148 related articles for article (PubMed ID: 34523851)
21. Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.
Bachanova V; Nachman PH
Bone Marrow Transplant; 2023 Nov; 58(11):1175-1176. PubMed ID: 37598289
[No Abstract] [Full Text] [Related]
22. Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.
Eder LN; Martinovic D; Mazzeo P; Ganster C; Hasenkamp J; Thomson J; Trummer A; Haase D; Wulf G
Curr Oncol; 2023 Jan; 30(1):1146-1150. PubMed ID: 36661736
[TBL] [Abstract][Full Text] [Related]
23. Management of Patients Undergoing CAR-T Cell Therapy in Germany.
Penack O; Dreger P; Ajib S; Ayuk F; Baermann BN; Bug G; Kriege O; Jentzsch M; Kobbe G; Koenecke C; Lutz M; Martin S; Schlegel PG; Schroers R; von Tresckow B; Vucinic V; Subklewe M; Bethge W; Wolff D
Oncol Res Treat; 2024; 47(3):65-75. PubMed ID: 38198763
[TBL] [Abstract][Full Text] [Related]
24. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy.
Bansal R; Vergidis P; Tosh PK; Wilson J; Hathcock M; Khurana A; Bennani NN; Paludo J; Villasboas JC; Wang Y; Ansell SM; Johnston PB; Freeman C; Lin Y
Transplant Cell Ther; 2024 Apr; 30(4):455.e1-455.e7. PubMed ID: 38346643
[TBL] [Abstract][Full Text] [Related]
25. Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Parikh RR; Milgrom SA; Campbell BA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1152-1158. PubMed ID: 38492961
[No Abstract] [Full Text] [Related]
26. Pseudo-progressive bone lesion in an infant leukemia after chimeric antigen receptor-T cell therapy.
Yokoyama S; Koga Y; Anan T; Kato K; Ohga S
Pediatr Int; 2023 Jan; 65(1):e15399. PubMed ID: 36307884
[No Abstract] [Full Text] [Related]
27. Bridging therapy before axi-cel for lymphoma.
Belbachir S; Purtill D
Blood Adv; 2024 Feb; 8(4):1051-1052. PubMed ID: 38411993
[No Abstract] [Full Text] [Related]
28. Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials.
Zhang D; Lyu L; Han S; Xu J; Hu G; Zhao Q; Hu Y
Int Immunopharmacol; 2024 Jan; 126():111273. PubMed ID: 38041957
[TBL] [Abstract][Full Text] [Related]
29. Can we truly define 'Fitness' for CAR-T therapy in large B cell lymphoma patients?
Chen AI; Maziarz RT
Chin Clin Oncol; 2024 Feb; 13(1):15. PubMed ID: 37953244
[No Abstract] [Full Text] [Related]
30. Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.
Ababneh HS; Frigault MJ; Ng AK; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3243. PubMed ID: 38103211
[No Abstract] [Full Text] [Related]
31. A ray of hope in a dire situation: Radiotherapy for progression after chimeric antigen receptor T-cell therapy.
Shakir R; Mikhaeel NG
Br J Haematol; 2020 Jul; 190(1):18-19. PubMed ID: 32130722
[No Abstract] [Full Text] [Related]
32. CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response.
Akhtar OS; Cao B; Wang X; Torka P; Al-Jumayli M; Locke FL; Freeman CL
Blood Adv; 2023 Oct; 7(19):5937-5940. PubMed ID: 37236167
[No Abstract] [Full Text] [Related]
33. [Exploration and practice of novel models of cellular therapy and hematopoietic stem cell transplantation].
Zhang X; Huang RH
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):105-108. PubMed ID: 38604784
[TBL] [Abstract][Full Text] [Related]
34. Management of neurotoxicity syndrome complicated by autologous hematopoietic stem cell transplantation bridge to chimeric antigen receptor T-Cell therapy: A case report.
Jiang P; Yang P; Wang W; Cao J; Chen W; Fu J; Lu L; Lu Y; Zhu X
Asia Pac J Oncol Nurs; 2024 Mar; 11(3):100368. PubMed ID: 38426045
[TBL] [Abstract][Full Text] [Related]
35. Two years later: CD19 CAR-T going the distance.
Darnell EP; Frigault MJ
Blood; 2024 Feb; 143(5):379-380. PubMed ID: 38300610
[No Abstract] [Full Text] [Related]
36. Long-term Survivors and Failures of CAR-T Therapy for Lymphoma: Is there a Role for Allogeneic Transplantation After the CAR-T Crash?
Spinner MA; Komanduri KV
Transplant Cell Ther; 2023 Dec; 29(12):725-726. PubMed ID: 38035887
[No Abstract] [Full Text] [Related]
37. [CAR-T cell therapy-related long-term cytopenias].
Li A; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):870-875. PubMed ID: 38049346
[No Abstract] [Full Text] [Related]
38. If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary.
Riedell PA; Downs C; Boehmer L; Ebmeier J; Porter D; Williams A
Transplant Cell Ther; 2024 Jan; 30(1):14-16. PubMed ID: 37918667
[No Abstract] [Full Text] [Related]
39. 'It's all gone': CAR-T therapy forces autoimmune diseases into remission.
Ledford H
Nature; 2023 Dec; 624(7992):483-484. PubMed ID: 38087105
[No Abstract] [Full Text] [Related]
40. Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Hemasphere; 2023 Nov; 7(11):e982. PubMed ID: 37920708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
